TrialThe British journal of dermatology2023

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).

Linda F Stein Gold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.